At its 2026 Annual Meeting of Stockholders held on June 26, 2026, Inhibikase Therapeutics, Inc. stockholders approved an amendment to the 2020 Equity Incentive Plan to increase the authorized share reserve by 3,000,000 shares. Stockholders also approved an amendment to the Certificate of Incorporation to limit the liability of certain officers. Inhibikase Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for inflammatory and inflammatory-related diseases.
